Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be a treatment for neurodegenerative diseases. Neurodegeneration, which involves the progressive loss of nerve structure and function, is a common characteristic of conditions, including Parkinson’s, Alzheimer’s and Huntington’s. Researchers from the University’s Institute of Translational Medicine have found that the anti-epileptic drug ethosuximide has protective effects in certain models relating to neurodegenerative diseases.

Gel research

Research by chemists at the University of York has revealed new information about bacterial gels. The research in the Department of Chemistry demonstrated that alginate gels, which can be produced as biofilms by bacteria, are more dynamic than previously thought. Understanding the dynamics may ultimately suggest new ways of helping prevent or better control such bacterial infections, which can be particularly critical in the lungs of cystic fibrosis patients. Dr Victor Chechik and Professor David Smith worked with visiting Romanian scientist Dr Gabriela Ionita on the research.

New deal

North-East based Cambridge Research Biochemicals (CRB) will continue to supply The Medical Research Council with custom-synthesised peptides and bespoke polyclonal and monoclonal antibodies for 12 months as a valued preferred supplier under a new pricing agreement. CRB has been operating in the life sciences field for 35 years and is based in Billingham on Teesside.